Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Other Working Capital Changes (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Other Working Capital Changes for 7 consecutive years, with $3.3 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Other Working Capital Changes rose 601.96% year-over-year to $3.3 million, compared with a TTM value of $3.3 million through Dec 2019, up 1750.75%, and an annual FY2024 reading of $8.5 million, up 694.84% over the prior year.
  • Other Working Capital Changes was $3.3 million for Q4 2019 at Larimar Therapeutics, up from -$22000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $3.3 million in Q4 2019 and bottomed at -$664000.0 in Q4 2018.
  • Average Other Working Capital Changes over 5 years is $180250.0, with a median of -$1000.0 recorded in 2017.
  • The sharpest move saw Other Working Capital Changes skyrocketed 784.09% in 2015, then tumbled 2635.0% in 2018.
  • Year by year, Other Working Capital Changes stood at -$183000.0 in 2015, then grew by 14.21% to -$157000.0 in 2016, then surged by 49.04% to -$80000.0 in 2017, then plummeted by 730.0% to -$664000.0 in 2018, then skyrocketed by 601.96% to $3.3 million in 2019.
  • Business Quant data shows Other Working Capital Changes for LRMR at $3.3 million in Q4 2019, -$22000.0 in Q3 2019, and $443000.0 in Q2 2019.